Show Summary Details
Page of

SIV and FIV Models of Peripheral Neuropathy 

SIV and FIV Models of Peripheral Neuropathy
SIV and FIV Models of Peripheral Neuropathy

Victoria A. Laast

, Gigi Ebenezer

, Justin C. McArthur

, and Joseph L. Mankowski

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 July 2020

Peripheral neuropathy frequently develops in HIV-infected patients. The most common clinical manifestation of HIV-induced peripheral nervous system (PNS) disease is Distal Sensory Polyneuropathy. Many HIV-infected individuals receiving combination antiretroviral therapy develop HIV-induced PNS disease despite effective suppression of HIV replication in both plasma and the cerebrospinal fluid. Complicating the picture further, treatment of HIV infection with nucleoside reverse transcriptase inhibitors can itself produce a peripheral neuropathy, known as anti-retrovival toxic neuropathy, that is clinically indistinguishable from HIV-mediated PNS damage. The fact that both HIV and antiretroviral treatment can damage the PNS complicates clinical studies of the pathogenesis of HIV-induced PNS disease. Animal models are essential to determine where and when initial neuronal injury occurs and to dissect out the effects of HIV infection from the effects of potentially neurotoxic antiretroviral drugs. This chapter provides a detailed overview of animal work in this area.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.